RSS-Feed abonnieren
DOI: 10.1055/s-0042-1760274
Updates on Preprocedural Evaluation and Patient Selection for Prostatic Artery Embolization

Abstract
Prostatic artery embolization (PAE) is a safe and effective treatment for benign prostatic hyperplasia. Patient evaluation is a critical and important part of this growing practice. History taking should include symptoms score evaluations for lower urinary tract symptoms, erectile function, and prostatitis symptoms score. The objective evaluations commonly include measurement of prostate specific antigen, postvoid residual volume, and uroflowmetry as well as urodynamic studies in selective patients. Imaging evaluation may include computed tomography angiography or magnetic resonance angiography, elucidating prostate volume, prostate gland morphology, vasculature, and prostate cancer. With evolving knowledge on PAE, we aim to discuss patient evaluation and selection based on updated evidence and discuss specific scenarios.
Keywords
prostate - embolization - benign prostatic hypertrophy - prostatic artery embolization - lower urinary tract symptoms - imaging - interventional radiologyPublikationsverlauf
Artikel online veröffentlicht:
20. Dezember 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012; 188 (02) 496-501
- 2 Simon RM, Howard LE, Moreira DM. et al. Does prostate size predict the development of incident lower urinary tract symptoms in men with mild to no current symptoms? Results from the REDUCE trial. Eur Urol 2016; 69 (05) 885-891
- 3 Franciosi M, Koff WJ, Rhoden EL. Correlation between the total volume, transitional zone volume of the prostate, transitional prostate zone index and lower urinary tract symptoms (LUTS). Int Urol Nephrol 2007; 39 (03) 871-877
- 4 Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: systematic review of the placebo arms of clinical trials. BJU Int 2008; 102 (08) 981-986
- 5 Alcaraz A, Carballido-Rodríguez J, Unda-Urzaiz M. et al. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment – the QUALIPROST study. Int Urol Nephrol 2016; 48 (05) 645-656
- 6 DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol 2000; 11 (06) 767-770
- 7 Powell T, Kellner D, Ayyagari R. Benign prostatic hyperplasia: clinical manifestations, imaging, and patient selection for prostate artery embolization. Tech Vasc Interv Radiol 2020; 23 (03) 100688
- 8 McConnell JD, Roehrborn CG, Bautista OM. et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349 (25) 2387-2398
- 9 Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36 (01) 1-13
- 10 van Kollenburg RAA, de Bruin DM, Wijkstra H. Validation of the electronic version of the International Index of Erectile Function (IIEF-5 and IIEF-15): a crossover study. J Med Internet Res 2019; 21 (07) e13490
- 11 Barbeau GR, Arsenault F, Dugas L, Simard S, Larivière MM. Evaluation of the ulnopalmar arterial arches with pulse oximetry and plethysmography: comparison with the Allen's test in 1010 patients. Am Heart J 2004; 147 (03) 489-493
- 12 Little MW, Macdonald AC, Boardman P. et al. Effects of sublingual glyceryl trinitrate administration on the quality of preprocedure CT angiography performed to plan prostate artery embolization. J Vasc Interv Radiol 2018; 29 (02) 225-228
- 13 Steffen P, Wentz R, Thaler C, Habermann CR, Zeile M. Single-center retrospective comparative study evaluating the benefit of computed tomography angiography prior to prostatic artery embolization. Cardiovasc Intervent Radiol 2022; 45 (07) 1019-1024
- 14 Desai H, Yu H, Ohana E, Gunnell ET, Kim J, Isaacson A. Comparative analysis of cone-beam CT angiogram and conventional CT angiogram for prostatic artery identification prior to embolization. J Vasc Interv Radiol 2018; 29 (02) 229-232
- 15 Vogl TJ, Booz C, Koch V. et al. Potential of pre-interventional magnetic resonance angiography for optimization of workflow and clinical outcome of prostatic arterial embolization. Eur J Radiol 2022; 150: 110236
- 16 Zhang JL, Wang MQ, Shen YG. et al. Effectiveness of contrast-enhanced MR angiography for visualization of the prostatic artery prior to prostatic arterial embolization. Radiology 2019; 291 (02) 370-378
- 17 Little MW, Boardman P, Macdonald AC. et al. Adenomatous-dominant benign prostatic hyperplasia (AdBPH) as a predictor for clinical success following prostate artery embolization: an age-matched case-control study. Cardiovasc Intervent Radiol 2017; 40 (05) 682-689
- 18 Tapping CR, Crew J, Proteroe A, Boardman P. Prostatic artery embolization (PAE) for prostatic origin bleeding in the context of prostate malignancy. Acta Radiol Open 2019; 8 (06) 2058460119846061
- 19 Tapping CR, Macdonald A, Hadi M. et al. Prostatic artery embolization (PAE) for benign prostatic hyperplasia (BPH) with haematuria in the absence of an upper urinary tract pathology. Cardiovasc Intervent Radiol 2018; 41 (08) 1160-1164
- 20 Bruno SM, Falagario UG, d'Altilia N. et al. PSA density help to identify patients with elevated PSA due to prostate cancer rather than intraprostatic inflammation: a prospective single center study. Front Oncol 2021; 11: 693684
- 21 Alam MU, Kumar J, Norez D. et al. Natural history, and impact of surgery and radiation on survival outcomes of men diagnosed with low-grade prostate cancer at ≤ 55 years of age: a 25-year follow-up of > 60,000 men. Int Urol Nephrol 2022;
- 22 Lloyd T, Hounsome L, Mehay A, Mee S, Verne J, Cooper A. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010. BMC Med 2015; 13: 171
- 23 Malling B, Røder MA, Lindh M, Frevert S, Brasso K, Lönn L. Palliative prostate artery embolization for prostate cancer: a case series. Cardiovasc Intervent Radiol 2019; 42 (10) 1405-1412
- 24 Parikh N, Keshishian E, Manley B. et al. Effectiveness and safety of prostatic artery embolization for the treatment of lower urinary tract symptoms from benign prostatic hyperplasia in men with concurrent localized prostate cancer. J Vasc Interv Radiol 2021; 32 (07) 1053-1061
- 25 Rastinehad AR, Caplin DM, Ost MC. et al. Selective arterial prostatic embolization (SAPE) for refractory hematuria of prostatic origin. Urology 2008; 71 (02) 181-184
- 26 Tian W, Zhou C, Leng B, Shi H, Liu S. Prostatic artery embolization for control of gross hematuria in patients with benign prostatic hyperplasia: a single-center retrospective study in 20 patients. J Vasc Interv Radiol 2019; 30 (05) 661-667
- 27 Sare A, Kothari P, Cieslak III JA. et al. Perioperative blood loss after preoperative prostatic artery embolization in patients undergoing simple prostatectomy: a propensity score‒matched study. J Vasc Interv Radiol 2021; 32 (08) 1113-1118
- 28 Gandhi J, Weissbart SJ, Kim AN, Joshi G, Kaplan SA, Khan SA. Clinical considerations for intravesical prostatic protrusion in the evaluation and management of bladder outlet obstruction secondary to benign prostatic hyperplasia. Curr Urol 2018; 12 (01) 6-12
- 29 Bilhim T, Betschart P, Lyatoshinsky P, Müllhaupt G, Abt D. Minimally invasive therapies for benign prostatic obstruction: a review of currently available techniques including prostatic artery embolization, water vapor thermal therapy, prostatic urethral lift, temporary implantable nitinol device and aquablation. Cardiovasc Intervent Radiol 2022; 45 (04) 415-424
- 30 Lin YT, Amouyal G, Thiounn N. et al. Intra-vesical prostatic protrusion (IPP) can be reduced by prostatic artery embolization. Cardiovasc Intervent Radiol 2016; 39 (05) 690-695
- 31 Ali R, Gabr A, Mouli SK. et al. MR imaging findings of the prostate gland following prostate artery embolization: results from a prospective phase 2 study. Abdom Radiol (NY) 2019; 44 (02) 713-722
- 32 Maron SZ, Sher A, Kim J, Lookstein RA, Rastinehad AR, Fischman A. Effect of median lobe enlargement on early prostatic artery embolization outcomes. J Vasc Interv Radiol 2020; 31 (03) 370-377
- 33 Meira M, de Assis AM, Moreira AM, Antunes AA, Carnevale FC, Srougi M. Intravesical prostatic protrusion does not influence the efficacy of prostatic artery embolization. J Vasc Interv Radiol 2021; 32 (01) 106-112
- 34 Picel AC, Hsieh TC, Shapiro RM, Vezeridis AM, Isaacson AJ. Prostatic artery embolization for benign prostatic hyperplasia: patient evaluation, anatomy, and technique for successful treatment. Radiographics 2019; 39 (05) 1526-1548
- 35 Amparore D, Fiori C, Valerio M. et al. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Prostate Cancer Prostatic Dis 2021; 24 (02) 349-357
- 36 McVary KT, Rogers T, Roehrborn CG. Rezūm water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. Urology 2019; 126: 171-179
- 37 Roehrborn CG, Barkin J, Gange SN. et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol 2017; 24 (03) 8802-8813
- 38 Desai M, Bidair M, Bhojani N. et al. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol 2020; 27 (02) 10147-10153
- 39 Wang M, Guo L, Duan F. et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. BJU Int 2016; 117 (01) 155-164
- 40 Parikh N, Keshishian E, Sharma A. et al. Prostatic artery embolization is safe and effective for medically recalcitrant radiation-induced prostatitis. Adv Radiat Oncol 2020; 5 (05) 905-909
- 41 Abt D, Hechelhammer L, Müllhaupt G. et al. Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial. BMJ 2018; 361: k2338
- 42 Insausti I, Sáez de Ocáriz A, Galbete A. et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol 2020; 31 (06) 882-890
- 43 Gao YA, Huang Y, Zhang R. et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate – a prospective, randomized, and controlled clinical trial. Radiology 2014; 270 (03) 920-928
- 44 Sajan A, Mehta T, Desai P, Isaacson A, Bagla S. Minimally invasive treatments for benign prostatic hyperplasia: systematic review and network meta-analysis. J Vasc Interv Radiol 2022; 33 (04) 359-367.e8
- 45 Ray AF, Powell J, Speakman MJ. et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int 2018; 122 (02) 270-282
- 46 Bhatia S, Acharya V, Jalaeian H. et al. Effect of prostate artery embolization on erectile function - a single center experience of 167 patients. J Sex Med 2022; 19 (04) 594-602
- 47 Uflacker A, Haskal ZJ, Bilhim T, Patrie J, Huber T, Pisco JM. Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol 2016; 27 (11) 1686-1697.e8
- 48 Knight GM, Talwar A, Salem R, Mouli S. Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Intervent Radiol 2021; 44 (02) 183-193